Nemaura Medical to Present at the Planet MIcroCap Showcase: Virtual 2022

Rhea-AI Summary

Nemaura Medical (Nasdaq: NMRD) will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 on December 7, 2022, at 9:00 AM EST. CEO Dr. Faz Chowdhury will discuss the company's innovative approach to non-invasive wearable diagnostic devices, including its flagship products sugarBEAT® and proBEAT™. These devices target diabetes management and aim to capitalize on the growing health-tech sector, projected to reach $60 billion by 2023. Investors can register for one-on-one meetings during the conference.

Loughborough, England, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces today that CEO Dr. Faz Chowdhury will present a corporate overview at the Planet MicroCap Showcase: Virtual 2022 being held on December 6 – 8, 2022.

Presentation Date: December 7, 2022
Time: 9:00am EST
Webcast Link: https://www.webcaster4.com/Webcast/Page/2937/47190

Dr. Chowdhury will be available for one-on-one investor meetings throughout the conference. To attend the conference and request a meeting, register here:

https://planetmicrocapshowcase.com/signup

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT^® to the U.S. FDA. proBEAT^™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT^®diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Contact:

Jules Abraham (Media)
CORE IR
917-885-7378
julesa@coreir.com

Bret Shapiro (Investors)
Senior Managing Partner
CORE IR
(561) 479.8566
brets@coreir.com

FAQ

What is the date and time of Nemaura Medical's presentation at the Planet MicroCap Showcase?

Nemaura Medical's presentation is scheduled for December 7, 2022, at 9:00 AM EST.

Who will present for Nemaura Medical at the virtual conference?

CEO Dr. Faz Chowdhury will present for Nemaura Medical.

What products is Nemaura Medical showcasing during the conference?

Nemaura Medical is showcasing its non-invasive wearable diagnostic devices, including sugarBEAT® and proBEAT™.

How can investors schedule a meeting with Nemaura Medical during the conference?

Investors can register for one-on-one meetings through the conference registration link.

What is the market size of the wearable health-tech sector related to diabetes?

The wearable health-tech sector is projected to reach $60 billion by 2023.